Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks
Executive Summary
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
You may also be interested in...
Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed
Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
Coronavirus Update: Trump Tests Positive, US Pause Remains On AstraZeneca Vaccine
Meanwhile, seven former US FDA commissioners issue joint plea for trust in the scientific integrity of the agency.
How Merck KgaA’s Life Science Unit Is Riding The Crest Of The Gene Therapy Wave
Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.